Atossa reports Q2 2026 results, completes enrollment in EVANGELINE trial

Atossa Therapeutics reported financial results for the quarter ended June 30, 2026, and gave a pipeline update on August 7, 2026.

In oncology, the company said EVANGELINE (NCT05607004) is an ongoing, multicenter, open-label Phase 2 study evaluating daily 40 mg (Z)-endoxifen plus goserelin administered every 28 days as neoadjuvant therapy in premenopausal women with ER+/HER2-negative, cT2-3, cN0-1 breast cancer.¹ The company said enrollment in this study was completed as of June 30, 2026.¹ Separately, Atossa published preclinical data showing that, in the company's words, "Effect of (Z)-endoxifen Demonstrates Robust Estrogen Receptor Signaling Inhibition Across Clinically Relevant ESR1 Mutations," and said these mutations drive acquired resistance to endocrine therapy in ER-positive breast cancer with few treatment options left once resistance develops, based on ESR1 mutations being a major mechanism of acquired endocrine resistance in ER-positive breast cancer that remain associated with limited treatment options despite newer endocrine therapies.¹

In rare diseases, Atossa presented data at an AACR conference describing what it called a dual mechanism of action for (Z)-endoxifen relevant to McCune-Albright Syndrome-associated Peripheral Precocious Puberty (MAS-PPP)¹, which the company said works by blocking estrogen receptor-mediated transcription downstream of autonomous estrogen production while also suppressing PKC-β/AKT-linked proliferative and cell-cycle signaling.¹ The company noted it previously received Rare Pediatric Disease designation from the FDA for (Z)-endoxifen for McCune-Albright Syndrome.¹ A separate manuscript examined whether the drug could support utrophin expression as a potential treatment for Duchenne Muscular Dystrophy that would not depend on the specific dystrophin mutation.¹

On financing, Atossa said it entered a registered direct offering that provided for issuance of 1,363,637 shares of common stock along with Series A and Series B warrants, raising $4.5 million in upfront gross proceeds with potential for up to an additional $12 million if the warrants are fully exercised in cash.¹ As of June 30, 2026, cash and cash equivalents were $26,094 thousand, compared with $41,299 thousand as of December 31, 2025.¹ Net loss for the quarter was $8,491 thousand, compared with $8,423 thousand for the same quarter in 2025.¹